San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute (IRCCS), Milan, Italy.
Front Immunol. 2020 Jun 30;11:1260. doi: 10.3389/fimmu.2020.01260. eCollection 2020.
The prominent role of dendritic cells (DC) in promoting tolerance and the development of methods to generate clinical grade products allowed the clinical application of tolerogenic DC (tolDC)-based therapies for controlling unwanted immune responses. We established an efficient method to generate tolerogenic human DC, producing supra-physiological levels of IL-10, by genetically engineering monocyte-derived DC with a bidirectional Lentiviral Vector (bdLV) encoding for IL-10 and a marker gene. DC are mature DC, modulate T cell responses, promote T regulatory cells, and are phenotypically and functionally stable upon stimulation. Adoptive transfer of human DC in a humanized mouse model dampens allogeneic T cell recall responses, while murine DC delays acute graft-vs.-host disease in mice. Our report outlines an efficient method to transduce human myeloid cells with large-size LV and shows that stable over-expression of IL-10 generates an effective cell product for future clinical applications in the contest of allogeneic transplantation.
树突状细胞(DC)在促进免疫耐受和开发临床级产品方面发挥着重要作用,这使得基于耐受原性树突状细胞(tolDC)的治疗方法能够用于控制不必要的免疫反应。我们建立了一种高效的方法,通过基因工程将单核细胞来源的树突状细胞与编码 IL-10 和标记基因的双向慢病毒载体(bdLV)进行工程改造,从而产生超生理水平的 IL-10。这些 DC 是成熟的 DC,能够调节 T 细胞反应,促进 T 调节细胞,并且在受到刺激时具有表型和功能稳定性。在人源化小鼠模型中过继转移人源 DC 可抑制同种异体 T 细胞的回忆反应,而鼠源 DC 可延缓小鼠急性移植物抗宿主病。我们的报告概述了一种用大尺寸 LV 转导人髓样细胞的有效方法,并表明 IL-10 的稳定过表达可产生有效的细胞产品,用于同种异体移植背景下的未来临床应用。